CN101668517B - 包含维生素d化合物和蜡质载体的口服控释组合物 - Google Patents
包含维生素d化合物和蜡质载体的口服控释组合物 Download PDFInfo
- Publication number
- CN101668517B CN101668517B CN200880013357.6A CN200880013357A CN101668517B CN 101668517 B CN101668517 B CN 101668517B CN 200880013357 A CN200880013357 A CN 200880013357A CN 101668517 B CN101668517 B CN 101668517B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- hydroxy
- preparation
- serum
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510005755.5A CN104523707B (zh) | 2007-04-25 | 2008-04-25 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91385307P | 2007-04-25 | 2007-04-25 | |
US60/913,853 | 2007-04-25 | ||
PCT/US2008/061579 WO2008134512A1 (en) | 2007-04-25 | 2008-04-25 | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510005755.5A Division CN104523707B (zh) | 2007-04-25 | 2008-04-25 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101668517A CN101668517A (zh) | 2010-03-10 |
CN101668517B true CN101668517B (zh) | 2016-03-02 |
Family
ID=39665965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510005755.5A Active CN104523707B (zh) | 2007-04-25 | 2008-04-25 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
CN200880013357.6A Active CN101668517B (zh) | 2007-04-25 | 2008-04-25 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510005755.5A Active CN104523707B (zh) | 2007-04-25 | 2008-04-25 | 包含维生素d化合物和蜡质载体的口服控释组合物 |
Country Status (16)
Country | Link |
---|---|
US (8) | US8361488B2 (hr) |
EP (6) | EP2481400B1 (hr) |
JP (4) | JP5501956B2 (hr) |
KR (6) | KR20190028822A (hr) |
CN (2) | CN104523707B (hr) |
CA (2) | CA2943032C (hr) |
DK (3) | DK3342405T3 (hr) |
ES (4) | ES2757517T3 (hr) |
HK (4) | HK1142013A1 (hr) |
HR (1) | HRP20231142T3 (hr) |
HU (1) | HUE063590T2 (hr) |
NO (1) | NO2020043I1 (hr) |
PL (3) | PL2481400T3 (hr) |
PT (3) | PT2481400E (hr) |
SI (2) | SI2481400T1 (hr) |
WO (1) | WO2008134512A1 (hr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883120A (zh) * | 2016-03-28 | 2018-11-23 | 欧普科爱尔兰环球控股有限公司 | 维生素d治疗方法 |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3095447T3 (da) | 2006-02-03 | 2022-01-31 | Opko Renal Llc | Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3 |
HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
CA2683514C (en) | 2007-04-25 | 2019-07-09 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
JP5647516B2 (ja) * | 2007-04-25 | 2014-12-24 | シトクロマ インコーポレイテッド | ビタミンd療法のための方法および化合物 |
CN104257667B (zh) | 2007-04-25 | 2019-06-04 | 欧普科Ip 控股Ii 有限公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 |
US20090060878A1 (en) * | 2007-09-04 | 2009-03-05 | The Procter & Gamble Company | Oral Compositions, Products And Methods Of Use |
EA201001283A1 (ru) * | 2008-02-13 | 2011-08-30 | ДСМ АйПи АССЕТС Б.В. | Комбинация витамина d и 25-гидроксивитамина d3 |
BRPI0907950A2 (pt) * | 2008-02-13 | 2015-08-04 | Dsm Ip Assets Bv | Tratamento de hiperglicemia com 25-hidroxivitamina d3 |
CN107412237A (zh) * | 2008-02-13 | 2017-12-01 | 帝斯曼知识产权资产管理有限公司 | 25‑羟基‑维生素d3用于影响人肌肉生理学的用途 |
EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
EP2659904B1 (en) | 2008-06-26 | 2015-09-16 | Orphazyme APS | Use of Hsp70 as a regulator of enzymatic activity |
PT2321273E (pt) * | 2008-07-24 | 2014-12-29 | Wisconsin Alumni Res Found | Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário |
AU2010300475A1 (en) * | 2009-09-30 | 2012-05-03 | The Regents Of The University Of California | Cofactors and methods for use for individuals |
EP2515865B1 (en) * | 2009-12-22 | 2016-12-14 | Leo Pharma A/S | Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
US20130023501A1 (en) * | 2009-12-22 | 2013-01-24 | Leo Pharma A/S | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
WO2011123476A1 (en) * | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
EP3626255A1 (en) | 2010-11-30 | 2020-03-25 | Orphazyme A/S | Methods for increasing intracellular activity of hsp70 |
GB2502032B (en) * | 2011-03-02 | 2015-03-04 | D3 Pharma Ltd | Stable Vitamin D3 Composition |
JP6049409B2 (ja) * | 2012-11-08 | 2016-12-21 | 中日本カプセル 株式会社 | ハードカプセルの製造方法 |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CN103142554B (zh) * | 2013-03-21 | 2014-11-12 | 青岛正大海尔制药有限公司 | 骨化三醇控释胶囊及其制备方法 |
US20140296190A1 (en) * | 2013-03-27 | 2014-10-02 | Dsm Ip Assets B.V. | Marketing the use of 25-hydroxyvitamin d3 to enhance cognition |
KR20150134402A (ko) * | 2013-03-27 | 2015-12-01 | 디에스엠 아이피 어셋츠 비.브이. | 집행 기능 향상을 위한 25-하이드록시비타민 d3의 용도 |
WO2015102996A1 (en) * | 2013-12-31 | 2015-07-09 | Grasso Frank J | Extremely high loading dose |
TWI645864B (zh) * | 2014-03-14 | 2019-01-01 | 歐科二代智財控股公司 | 經穩定之修飾釋放維他命d調配物及其服用方法 |
TWI812891B (zh) * | 2014-03-14 | 2023-08-21 | 開曼群島商歐科二代智財控股公司 | 經穩定之修飾釋放維他命d調配物及其服用方法 |
EP3193925A2 (en) | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
PL3193840T3 (pl) | 2014-09-15 | 2021-12-06 | Orphazyme A/S | Preparat arimoklomolu |
ES2929218T3 (es) * | 2015-01-12 | 2022-11-28 | Enteris Biopharma Inc | Formas farmacéuticas orales sólidas |
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
US20180169034A1 (en) | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
JP6851868B2 (ja) * | 2016-03-23 | 2021-03-31 | 株式会社ファンケル | ビタミンd3安定化組成物 |
EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
ES2831764T3 (es) | 2016-04-29 | 2021-06-09 | Orphazyme As | Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa |
KR102108153B1 (ko) * | 2017-07-05 | 2020-05-07 | (주)동구바이오제약 | 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물 |
CN112074275A (zh) | 2018-04-03 | 2020-12-11 | 欧普科爱尔兰环球控股有限公司 | 骨化二醇在肥胖症治疗手术患者中的用途 |
BR112021003788A2 (pt) | 2018-08-31 | 2021-06-08 | Opko Ireland Global Holdings, Ltd. | formas de dosagem pediátrica, métodos de fabricação e uso de vitamina d |
US20220226351A1 (en) | 2019-02-06 | 2022-07-21 | Eirgen Pharma Ltd. | Method of Controlling Progression of Hyperparathyroidism, And Compositions for Use Therein |
EP3708171A1 (en) * | 2019-03-11 | 2020-09-16 | Roger Bouillon | Treatment of vitamin d deficiency with 25(oh) vitamin d in critically ill patients |
WO2021050697A1 (en) * | 2019-09-11 | 2021-03-18 | Barlean's Organic Oils, Llc | Softgel fill materials |
CN116033940A (zh) * | 2020-04-06 | 2023-04-28 | 艾尔金制药有限公司 | 激活内源性抗菌药物治疗sars-cov-2感染 |
BR112022019191A2 (pt) * | 2020-04-07 | 2022-11-01 | Carbogen Amcis B V | 25-hidroxivitamina d2 e/ou d3 para uso em obesidade |
CN115768412A (zh) * | 2020-05-31 | 2023-03-07 | 艾尔金制药有限公司 | 硬胶囊剂型和其用途 |
KR20230128462A (ko) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008517A2 (en) * | 1996-08-26 | 1998-03-05 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol |
US3565924A (en) * | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
US3880894A (en) * | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
US4004003A (en) * | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
US4335120A (en) * | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4230701A (en) * | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
JPS5832823A (ja) | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | 脱癌剤 |
JPS5832823U (ja) | 1981-08-27 | 1983-03-03 | 銅金株式会社 | 金属屋根板用吊子 |
JPS58206524A (ja) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
JPS59155309A (ja) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | 活性型ビタミンd↓3類組成物 |
US4684524A (en) * | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
US4555364A (en) * | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
US4668517A (en) * | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
DE3676235D1 (de) * | 1985-06-04 | 1991-01-31 | Teijin Ltd | Arzneizubereitung mit verzoegerter wirkstoffabgabe. |
JPS61293911A (ja) | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
US5104864A (en) * | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンd▲下3▼類固型製剤 |
JPH02240024A (ja) | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンd↓3類製剤用組成物 |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
GB9004544D0 (en) * | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
JP2845342B2 (ja) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンd▲下3▼誘導体含有固形製剤組成物 |
JPH04198129A (ja) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 活性型ビタミンd↓3類含有組成物 |
JP2893140B2 (ja) | 1990-11-30 | 1999-05-17 | エスエス製薬株式会社 | 安定なビタミンd製剤 |
JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンd3類軟カプセル剤の製造方法 |
NZ242271A (en) * | 1991-04-09 | 1993-10-26 | Takeda Chemical Industries Ltd | Medicaments containing a vitamin d compound stabilised by a basic substance |
US5693615A (en) * | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
NZ254424A (en) * | 1992-06-22 | 1997-09-22 | Lunar Corp | Pharmaceutical composition and use of 1 alpha hydroxy-pre-vitamin d |
US5354743A (en) * | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
JPH07242550A (ja) | 1994-03-02 | 1995-09-19 | Teijin Ltd | 二次性副甲状腺機能亢進症治療剤 |
IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
EP0769936A1 (en) | 1994-07-22 | 1997-05-02 | G.D. Searle & Co. | Self-emulsifying drug delivery system |
JPH0892098A (ja) | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
PL183499B1 (pl) | 1994-10-21 | 2002-06-28 | Nps Pharma Inc | Związki do modulowania receptorów wapniowych i kompozycje farmaceutyczne |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
US6376479B1 (en) * | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
JP3372259B2 (ja) | 1995-09-21 | 2003-01-27 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | カルシトリオール誘導体およびそれらの用途 |
DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
NO971934L (no) | 1996-05-23 | 1997-11-24 | Hoffmann La Roche | Flourinerte vitamin D3 -analoger |
US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
AU744156B2 (en) | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
JPH10158171A (ja) | 1996-12-02 | 1998-06-16 | Kita:Kk | ビタミンd化合物を配合した眼内投与剤 |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
EP1009387B1 (en) | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
JPH1175863A (ja) | 1997-07-10 | 1999-03-23 | Kyowa Hakko Kogyo Co Ltd | 25−ヒドロキシビタミンD3−1α−水酸化酵素および該酵素をコードするDNA |
US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
AU9376998A (en) | 1997-09-02 | 1999-03-22 | Johns Hopkins University School Of Medicine, The | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
JPH11158074A (ja) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | 高アミノ酸付加活性型ビタミンd強化組成物 |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
EP1066377A1 (en) | 1998-03-25 | 2001-01-10 | Cutanogen, Inc. | Methods for prevention and treatment of cancer |
CA2326117A1 (en) | 1998-03-27 | 1999-10-07 | Oregon Health Sciences University | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US8133694B2 (en) | 1998-06-25 | 2012-03-13 | Immundiagnostik Ag | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D |
US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
HUP0100437A3 (en) | 1998-08-27 | 2002-08-28 | Pharmacia And Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
CA2345815C (en) | 1998-10-09 | 2011-02-08 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
JP2000206312A (ja) | 1998-11-12 | 2000-07-28 | Olympus Optical Co Ltd | 光学素子 |
DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6432936B1 (en) * | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1180035B1 (en) * | 1999-04-01 | 2006-11-02 | Johns Hopkins University | NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1-alpha, 25-DIHYDROXY VITAMIN D3 |
US7648826B1 (en) | 1999-04-02 | 2010-01-19 | The Regents Of The University Of California | Detecting CYP24 expression level as a marker for predisposition to cancer |
DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
WO2000072831A1 (en) * | 1999-05-27 | 2000-12-07 | Drugtech Corporation | Nutritional formulations |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US6051567A (en) * | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
US6274169B1 (en) * | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
WO2001015702A1 (fr) | 1999-08-31 | 2001-03-08 | Chugai Seiyaku Kabushiki Kaisha | Capsules molles |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
JP2004504295A (ja) | 2000-07-18 | 2004-02-12 | ボーン ケア インターナショナル インコーポレイテッド | 安定化1α−ヒドロキシビタミンD |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
EP1323404B1 (en) | 2000-08-29 | 2013-10-16 | Nisshin Kasei Co.,Ltd. | Hard capsule |
US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
US6479649B1 (en) | 2000-12-13 | 2002-11-12 | Fmc Corporation | Production of carrageenan and carrageenan products |
JP2002302447A (ja) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | 局所投与用癌治療剤 |
RU2262922C2 (ru) | 2001-05-15 | 2005-10-27 | Уорнер-Ламберт Компани Ллс | Способ прессования для получения лекарственной формы фенитоина натрия |
AU2002315779B2 (en) | 2001-07-05 | 2007-03-22 | Wakunaga Pharmaceutical Co.,Ltd | Soft capsules |
US6870833B2 (en) | 2001-07-20 | 2005-03-22 | Net2Phone, Inc. | Active voice messaging |
US7166585B2 (en) | 2001-08-22 | 2007-01-23 | Cytochroma Inc. | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
KR100688618B1 (ko) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | 비타민 d 경구투여용 서방성 약제 조성물 |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
EP1436257B1 (en) * | 2001-10-12 | 2007-04-18 | Johns Hopkins University | Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
CN100335133C (zh) | 2001-11-22 | 2007-09-05 | 森下仁丹株式会社 | 非胶凝状的胶囊膜组合物和使用其所形成的胶囊 |
GB0128415D0 (en) | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
KR20050044655A (ko) * | 2001-12-03 | 2005-05-12 | 노바세아, 인크. | 활성 비타민 d 화합물을 함유하는 약제학적 조성물 |
US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
FR2829142B1 (fr) | 2001-12-27 | 2004-02-13 | Ulice | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues |
US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US6949256B2 (en) | 2002-01-18 | 2005-09-27 | Banner Pharmacaps, Inc. | Non-gelatin capsule shell formulation |
NO20021592D0 (no) | 2002-04-04 | 2002-04-04 | Fmc Biopolymer As | Polysakkaridkapsler og fremgangsmåte ved fremstilling derav |
JP2005531532A (ja) | 2002-04-05 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | アレンドロナートおよびビタミンd製剤を用いる骨吸収阻害法 |
NZ536267A (en) | 2002-04-10 | 2007-06-29 | Fred H Miller | Multi-phase, multi-compartment and multi-ingredient capsular system |
US7288407B2 (en) | 2002-05-02 | 2007-10-30 | Cytochroma, Inc. | Stable cytochrome P450 24 (CYP24) expressing cell line and methods and uses thereof |
WO2003106411A1 (en) | 2002-06-13 | 2003-12-24 | Johns Hopkins University | 24-sulfoximine vitamin d3 compounds |
EP1519717B1 (en) | 2002-07-05 | 2010-09-29 | Temrel Limited | Controlled release composition |
MY142179A (en) | 2002-07-25 | 2010-10-15 | Glaxo Group Ltd | Multicomponent pharmaceutical dosage form |
ATE373472T1 (de) | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
AU2002368245A1 (en) | 2002-09-26 | 2004-04-19 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2004175750A (ja) | 2002-11-28 | 2004-06-24 | Kose Corp | 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤 |
US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
DE20321698U1 (de) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats |
WO2004058235A2 (en) | 2002-12-16 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
AU2003292920A1 (en) | 2002-12-18 | 2004-07-09 | Cytochroma Inc. | 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
CA2515641A1 (en) | 2003-02-11 | 2004-08-26 | Alza Corporation | Methods and dosage forms with modified layer geometry |
WO2004091533A2 (en) | 2003-04-14 | 2004-10-28 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
US20070032461A1 (en) | 2003-04-30 | 2007-02-08 | Bioxell S.P.A. | 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
US20060216358A1 (en) | 2003-05-07 | 2006-09-28 | Christian Hansen | Controlled release composition containing a strontium salt |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
CA2529495C (en) | 2003-06-16 | 2013-02-05 | Solx, Inc. | Shunt for the treatment of glaucoma |
ATE536861T1 (de) | 2003-06-26 | 2011-12-15 | Control Delivery Sys Inc | Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung |
AU2003903382A0 (en) | 2003-07-03 | 2003-07-17 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof |
WO2005002549A1 (en) | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
US20050124591A1 (en) * | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
US20050148557A1 (en) * | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
SI3395339T1 (sl) | 2003-09-12 | 2019-08-30 | Amgen, Inc, | Hitrotopna formulacija, ki vsebuje cinakalcet HCL |
JP2007512371A (ja) | 2003-11-25 | 2007-05-17 | デルタノイド ファーマシューティカルズ,インコーポレイティド | ビタミン化合物を用いる体脂肪の減少方法 |
US7427670B2 (en) | 2003-12-19 | 2008-09-23 | Cytochroma Inc. | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
WO2005123120A1 (en) | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
WO2006007323A2 (en) | 2004-06-28 | 2006-01-19 | Alza Corporation | Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
KR20070043806A (ko) | 2004-07-29 | 2007-04-25 | 사노피-아벤티스 | pH에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제 |
US8231896B2 (en) | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
US7067568B1 (en) | 2004-12-03 | 2006-06-27 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
CA2604943C (en) | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
US9205047B2 (en) | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
AR055099A1 (es) | 2005-07-28 | 2007-08-08 | Alza Corp | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol |
ES2323900T3 (es) | 2005-09-29 | 2009-07-27 | F. Hoffmann-La Roche Ag | Anticuerpos contra la 25-hidroxivitamina d. |
ITFI20050206A1 (it) | 2005-09-30 | 2007-04-01 | Valpharma Sa | Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione |
CA2924200C (en) | 2005-10-12 | 2017-09-05 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
JP5406529B2 (ja) | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
CA2627292C (en) | 2005-10-26 | 2012-04-17 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system |
JP5364377B2 (ja) | 2005-11-01 | 2013-12-11 | シー・ピー・ケルコ・ユー・エス・インコーポレイテツド | 高粘度ジウタンガムおよび生成法 |
WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
MXPA05014091A (es) | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus |
WO2007092221A2 (en) | 2006-01-31 | 2007-08-16 | Health Research Inc. | Method for identifying altered vitamin d metabolism |
US7528122B2 (en) | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
DK3095447T3 (da) | 2006-02-03 | 2022-01-31 | Opko Renal Llc | Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3 |
GB0606426D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
WO2007146004A1 (en) | 2006-06-06 | 2007-12-21 | Fmc Corporation | Kappa-2 carrageenan composition and products made therefrom |
US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
EP1912400A1 (en) | 2006-10-10 | 2008-04-16 | Matsushita Electric Industrial Co., Ltd. | Method and apparatus for mobile IP route optimization |
CA2667167C (en) | 2006-10-27 | 2014-02-18 | Pfizer Products Inc. | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
US8501717B2 (en) | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
US8491937B2 (en) | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
EP2135345A4 (en) | 2007-03-20 | 2016-12-14 | Electrolock Inc | ROEBEL WINDING WITH CONDUCTIVE FELT |
US20100144679A1 (en) | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
JP5647516B2 (ja) | 2007-04-25 | 2014-12-24 | シトクロマ インコーポレイテッド | ビタミンd療法のための方法および化合物 |
CA2683514C (en) | 2007-04-25 | 2019-07-09 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
CN104257667B (zh) | 2007-04-25 | 2019-06-04 | 欧普科Ip 控股Ii 有限公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 |
KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
KR100836960B1 (ko) | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | 새로운 나이아신 제어방출형 제제 |
EP2042165A1 (de) | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
EP2229155A4 (en) | 2007-12-12 | 2010-12-29 | Northern Innovations And Formulations Corp | PARTICLES IN A CAPSULE |
BRPI0907950A2 (pt) | 2008-02-13 | 2015-08-04 | Dsm Ip Assets Bv | Tratamento de hiperglicemia com 25-hidroxivitamina d3 |
CN107412237A (zh) | 2008-02-13 | 2017-12-01 | 帝斯曼知识产权资产管理有限公司 | 25‑羟基‑维生素d3用于影响人肌肉生理学的用途 |
MX2010008896A (es) | 2008-02-13 | 2010-11-05 | Dsm Ip Assets Bv | Tratamiento de hipertension con 25-hidroxi-vitamina d3. |
EA201001283A1 (ru) | 2008-02-13 | 2011-08-30 | ДСМ АйПи АССЕТС Б.В. | Комбинация витамина d и 25-гидроксивитамина d3 |
EA018580B1 (ru) | 2008-02-13 | 2013-09-30 | ДСМ АйПи АССЕТС Б.В. | Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза |
EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
PT2321273E (pt) | 2008-07-24 | 2014-12-29 | Wisconsin Alumni Res Found | Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário |
SI2341899T1 (sl) | 2008-09-24 | 2015-04-30 | Evonik Roehm Gmbh | Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola |
ES2425762T3 (es) | 2008-10-27 | 2013-10-17 | Roquette Freres | Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon |
MX2011007817A (es) | 2009-01-23 | 2011-09-21 | A F S P A Aziende Chimichi Riunite Angelini Francesco A C R | Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion. |
CH700543A2 (de) | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
BR112012005452B1 (pt) | 2009-09-10 | 2021-05-11 | DuPont Nutrition USA, Inc. | cápsula de alginato sem costura, e, método para fabricar uma cápsula de alginato sem costura |
IT1396937B1 (it) | 2009-11-26 | 2012-12-20 | Bruzzese | Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea |
FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
US8101203B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
KR20120005228A (ko) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법 |
KR101288079B1 (ko) | 2010-08-04 | 2013-07-22 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 연질캡슐용 막 형성 조성물 |
US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
US20130252927A1 (en) | 2010-12-06 | 2013-09-26 | Dsm Ip Assets, B.V. | Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3 |
CA2821415C (en) | 2010-12-28 | 2017-08-01 | Future Diagnostics B.V. | Release reagent for vitamin d |
GB2502032B (en) | 2011-03-02 | 2015-03-04 | D3 Pharma Ltd | Stable Vitamin D3 Composition |
MX2013012165A (es) | 2011-04-20 | 2014-06-11 | Mico Bio Inc | Composicion y metodo para mejorar una respuesta inmune. |
US8992971B2 (en) | 2011-04-20 | 2015-03-31 | Suheung Capsule Co., Ltd. | Non-animal soft capsule shell composition having improved disintegration and shell hardness |
CN102771688A (zh) | 2011-05-13 | 2012-11-14 | 富曼实(上海)商贸有限公司 | 可食用液体填充的多糖胶囊 |
US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
PT106978A (pt) | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
EP2815745A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte und Lizenzen AG | Soft shell capsule and process for its manufacture |
CN103520133B (zh) | 2013-10-26 | 2015-02-04 | 中山市凯博思淀粉材料科技有限公司 | 一种淀粉基软胶囊的制备方法 |
CN103495176B (zh) | 2013-10-26 | 2015-01-28 | 中山市凯博思淀粉材料科技有限公司 | 一种共混挤出法制备淀粉基软胶囊的方法 |
EP3193925A2 (en) | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
-
2008
- 2008-04-25 KR KR1020197007218A patent/KR20190028822A/ko not_active Application Discontinuation
- 2008-04-25 KR KR1020167036353A patent/KR101759244B1/ko active IP Right Grant
- 2008-04-25 EP EP12154573.5A patent/EP2481400B1/en active Active
- 2008-04-25 PT PT121545735T patent/PT2481400E/pt unknown
- 2008-04-25 CA CA2943032A patent/CA2943032C/en active Active
- 2008-04-25 ES ES18154616T patent/ES2757517T3/es active Active
- 2008-04-25 CN CN201510005755.5A patent/CN104523707B/zh active Active
- 2008-04-25 KR KR1020147030441A patent/KR101691876B1/ko active IP Right Grant
- 2008-04-25 PL PL12154573T patent/PL2481400T3/pl unknown
- 2008-04-25 WO PCT/US2008/061579 patent/WO2008134512A1/en active Application Filing
- 2008-04-25 PL PL19172946.6T patent/PL3542792T3/pl unknown
- 2008-04-25 SI SI200831282T patent/SI2481400T1/sl unknown
- 2008-04-25 EP EP08746908A patent/EP2148661B1/en active Active
- 2008-04-25 PL PL08746908T patent/PL2148661T3/pl unknown
- 2008-04-25 ES ES12154573.5T patent/ES2496915T3/es active Active
- 2008-04-25 ES ES08746908T patent/ES2401205T3/es active Active
- 2008-04-25 DK DK18154616T patent/DK3342405T3/da active
- 2008-04-25 DK DK08746908.6T patent/DK2148661T3/da active
- 2008-04-25 ES ES19172946T patent/ES2956794T3/es active Active
- 2008-04-25 US US12/109,983 patent/US8361488B2/en active Active
- 2008-04-25 KR KR1020197036963A patent/KR20190141269A/ko not_active Application Discontinuation
- 2008-04-25 CA CA2683997A patent/CA2683997C/en active Active
- 2008-04-25 JP JP2010506520A patent/JP5501956B2/ja active Active
- 2008-04-25 CN CN200880013357.6A patent/CN101668517B/zh active Active
- 2008-04-25 DK DK12154573.5T patent/DK2481400T3/da active
- 2008-04-25 EP EP19172946.6A patent/EP3542792B1/en active Active
- 2008-04-25 PT PT87469086T patent/PT2148661E/pt unknown
- 2008-04-25 HU HUE19172946A patent/HUE063590T2/hu unknown
- 2008-04-25 EP EP18154616.9A patent/EP3342405B1/en active Active
- 2008-04-25 HR HRP20231142TT patent/HRP20231142T3/hr unknown
- 2008-04-25 EP EP14166756.8A patent/EP2762132A1/en not_active Ceased
- 2008-04-25 KR KR1020097024328A patent/KR101540369B1/ko active IP Right Grant
- 2008-04-25 PT PT181546169T patent/PT3342405T/pt unknown
- 2008-04-25 SI SI200830899T patent/SI2148661T1/sl unknown
- 2008-04-25 KR KR1020177019172A patent/KR101959952B1/ko active IP Right Grant
- 2008-04-25 EP EP23175825.1A patent/EP4248952A1/en active Pending
-
2010
- 2010-09-10 HK HK10108648.7A patent/HK1142013A1/zh unknown
-
2011
- 2011-09-26 US US13/244,945 patent/US8207149B2/en active Active
-
2013
- 2013-01-22 US US13/746,982 patent/US8778373B2/en active Active
- 2013-02-01 HK HK13101470.2A patent/HK1174538A1/xx unknown
- 2013-11-22 JP JP2013241875A patent/JP5931042B2/ja active Active
-
2014
- 2014-06-16 US US14/305,863 patent/US9918940B2/en active Active
-
2015
- 2015-02-06 HK HK15101345.3A patent/HK1200732A1/xx unknown
- 2015-04-17 US US14/690,131 patent/US9408858B2/en active Active
- 2015-10-13 HK HK15109994.0A patent/HK1209322A1/xx unknown
-
2016
- 2016-04-26 JP JP2016087776A patent/JP6236657B2/ja active Active
- 2016-08-08 US US15/231,357 patent/US9498486B1/en active Active
- 2016-11-21 US US15/358,065 patent/US9925147B2/en active Active
-
2017
- 2017-10-04 JP JP2017194134A patent/JP6530028B2/ja active Active
- 2017-10-05 US US15/726,046 patent/US11154509B2/en active Active
-
2020
- 2020-12-02 NO NO2020043C patent/NO2020043I1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883120A (zh) * | 2016-03-28 | 2018-11-23 | 欧普科爱尔兰环球控股有限公司 | 维生素d治疗方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101668517B (zh) | 包含维生素d化合物和蜡质载体的口服控释组合物 | |
US20230346804A1 (en) | Methods and compositions for reducing parathyroid levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142013 Country of ref document: HK |
|
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: BISHOP CHARLES W. Inventor after: HELVIG CHRISTIAN Inventor after: AGUDOAWU SAMMY A. Inventor after: WHITE JAY A. Inventor after: CRAWFORD KEITH H. Inventor after: MESSNER ERIC J. Inventor after: Petkovich P. Martin Inventor before: HELVIG CHRISTIAN Inventor before: WHITE JAY A. Inventor before: BISHOP CHARLES W. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TABASH SAMIR P. WHITE JAY A. BISHOP CHARLES W. TO: BISHOP CHARLES W. TABASH SAMIR P. AGUDOAWU SAMMY A. WHITE JAY A. CRAWFORD KEITH H. ERIC. J. MESSNER PETKOVICH P. MARTIN |
|
ASS | Succession or assignment of patent right |
Owner name: OUPUKE IP HOLDING II CO., LTD. Free format text: FORMER OWNER: CYTOCHROMA CAYMAN ISLANDS CO., LTD. Effective date: 20141222 Owner name: OPKO HEALTH, INC. Free format text: FORMER OWNER: PROVENTIV THERAPEUTICS LLC Effective date: 20141222 Owner name: OPKO RENAL LLC Free format text: FORMER OWNER: OPKO HEALTH, INC. Effective date: 20141222 Owner name: CYTOCHROMA CAYMAN ISLANDS CO., LTD. Free format text: FORMER OWNER: CYTOCHROMA INC.;PROVENTIV THERAPEUTICS LLC Effective date: 20141222 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20141222 Address after: American Florida Applicant after: CYTOCHROMA Inc. Applicant after: OPKO RENAL, LLC Address before: Cayman Islands Applicant before: Cayman Cayman Islands Ltd. Applicant before: Best health Co.,Ltd. Effective date of registration: 20141222 Address after: Cayman Islands Applicant after: Cayman Cayman Islands Ltd. Applicant after: Best health Co.,Ltd. Address before: Ontario Applicant before: CYTOCHROMA, Inc. Applicant before: Proventiv Therapeutics LLC |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1142013 Country of ref document: HK |